31 completed, 8 recruiting, 5 active not recruiting, 5 terminated. 55 Phase 1, 18 Phase 2.
Follow Neoplasms, Basal Cell: new trials by email Literature Review of Neoplasms, Basal Cell trials Research Report on Neoplasms, Basal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors KUP-101A - Cutaneous Melanoma, Mucosal Melanoma | Phase 1 | Recruiting | Kupando GmbH | 21 | 2026-07-03 | 2026-08-12 |
| R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors R-5780 - Solid Tumor, Adult, Solid Tumor | Phase 1 | Recruiting | Rise Therapeutics LLC | 33 | 2025-08-01 | 2026-09-18 |
| Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment Tirbanibulin ointment 1%, non-ablative fractional laser - Keratinocyte Carcinoma, Basal Cell Carcinomas | Phase 1 / Phase 2 | Recruiting | Bruce Robinson, MD | 100 | 2025-05-16 | 2025-09-17 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas aminolevulinic acid HCL (ALA), BLU-U device model 4170E - Basal Cell Carcinoma (BCC) | Phase 1 | Recruiting | Nathalie Zeitouni | 20 | 2024-10-07 | 2026-01-29 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| Intratumoral phIL12 GET phIL12 GET - Basal Cell Carcinoma | Phase 1 | Completed | Institute of Oncology Ljubljana | 9 | 2021-09-28 | 2023-12-14 |
| Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) Doxorubicin-containing MNA, Placebo-containing MNA - Basal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | SkinJect, Inc. | 25 | 2021-09-24 | 2023-04-14 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| IFx-Hu2.0 for the Treatment of Patients With Skin Cancer IFx-Hu2.0 - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Completed | TuHURA Biosciences, Inc. | 5 | 2021-06-10 | 2024-08-02 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors INCB099318 - Advanced Solid Tumors, MSI-H/dMMR Tumors | Phase 1 | Terminated | Incyte Corporation | 105 | 2021-03-26 | 2025-10-16 |
| Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer Imvamune - Non-melanoma Skin Cancer, Basal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ivan Litvinov | 1 | 2020-11-16 | 2024-03-07 |
| Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype AIV001, AIV001 suspension - Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma | Phase 1 | Completed | AiViva BioPharma, Inc. | 26 | 2020-08-18 | 2026-11-04 |
| Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC) Placebo-containing MNA, 25 µg doxorubicin-containing MNA, 50 µg doxorubicin-containing MNA - Basal Cell Carcinoma | Phase 1 | Terminated | SkinJect, Inc. | 13 | 2020-06-10 | 2026-04-16 |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies RP1, intra-tumoral injection, oncolytic virus - Merkel Cell Carcinoma, Basal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Replimune, Inc. | 69 | 2020-05-15 | 2026-04-22 |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Ipilimumab, Nivolumab, Prednisone - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2019-11-08 | 2026-11-13 |
| A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors Copaxone - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 | Unknown | University of Kansas Medical Center | 10 | 2019-07-26 | 2023-05-19 |
Showing 20 of 55. Sign in to see all of them.
Carcinoma, Basal Cell (52) · Skin Neoplasms (14) · Melanoma (12) · Carcinoma, Merkel Cell (9) · Carcinoma, Squamous Cell (7) · Neoplasms (6) · Basal Cell Nevus Syndrome (5) · Squamous Cell Carcinoma of Head and Neck (5) · Breast Neoplasms (4) · Endometrial Neoplasms (4) · Lymphoma, T-Cell, Cutaneous (4) · Medulloblastoma (4) · Neoplasm Metastasis (4) · Small Cell Lung Carcinoma (4)
Neoplasms by Histologic Type (55) · Neoplasms, Glandular and Epithelial (55) · Carcinoma (51) · Neoplasms (49) · Neoplasms by Site (24) · Skin Diseases (22) · Skin and Connective Tissue Diseases (22) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neuroendocrine Tumors (15) · Nevi and Melanomas (12) · Adenocarcinoma (10) · DNA Virus Infections (10)
1-phenyl-3,3-dimethyltriazene (5) · Photochemotherapy (5) · pembrolizumab (4) · Biopsy (3) · HhAntag691 (3) · Aminolevulinic Acid (2) · CTLA-4 Antigen (2) · Fluorouracil (2) · Ipilimumab (2) · Irinotecan (2) · Nivolumab (2) · Prednisone (2) · Sirolimus (2) · deltacortene (2) · gusacitinib (2)
Case Comprehensive Cancer Center (3) · Novartis Pharmaceuticals (3) · Shahid Beheshti University of Medical Sciences (3) · Ascend Biopharmaceuticals Ltd (2) · Merete Haedersdal (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · SkinJect, Inc. (2) · AiViva BioPharma, Inc. (1) · Anne Chang (1) · Blaze Bioscience Australia Pty Ltd (1) · Bristol-Myers Squibb (1) · Bruce Robinson, MD (1) · Eastern Virginia Medical School (1) · Genentech, Inc. (1)
United States (38) · Australia (4) · Canada (4) · Switzerland (4) · United Kingdom (4) · Denmark (3) · Spain (3) · Finland (2) · Netherlands (2) · Belgium (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · Ireland (1)
Evan J Lipson (2) · Zohreh Tehranchi-nia, assist.prof. (2) · Allan R. Oseroff, MD, PhD (1) · Allen E. Bale, MD (1) · Anna Bar (1) · Anne Lynn S Chang, MD (1) · Antoinette F. Hood, MD (1) · Arash Yavari, MBBS (1) · Ashwin Somasundaram, MD (1) · Bruce Robinson, MD (1) · Clement Leong (1) · Edward V. Maytin, MD, PhD (1)
PMID 19196482, PMID 20855696, PMID 27467121, PMID 28250200, PMID 32503950, PMID 34401600, PMID 35276694, PMID 36821617, PMID 38252910, PMID 38758815, PMID 39400600, PMID 40230575, PMID 42580817
2023 (2), P30CA043703 (2), UM1CA186691 (2), 2008 (1), 2009 (1), 2014 (1), 2019 (1), 2025 (1), P30CA016056 (1), P30CA124435 (1), R21CA109670 (1), U01CA062502 (1)